318 related articles for article (PubMed ID: 1569444)
21. Carboplatin in the treatment of carcinoma of the ovary: the National Cancer Institute of Canada experience. Ovarian Cancer Subcommittee.
Swenerton KD; Pater JL
Semin Oncol; 1992 Feb; 19(1 Suppl 2):114-9. PubMed ID: 1411622
[TBL] [Abstract][Full Text] [Related]
22. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest.
Conte PF; Bruzzone M; Carnino F; Gadducci A; Algeri R; Bellini A; Boccardo F; Brunetti I; Catsafados E; Chiara S; Foglia G; Gallo L; Iskra L; Mammoliti S; Parodi G; Ragni N; Rosso R; Rugiati S; Rubagotti A
J Clin Oncol; 1996 Feb; 14(2):351-6. PubMed ID: 8636743
[TBL] [Abstract][Full Text] [Related]
23. Lack of impact of platinum dose intensity on the outcome of ovarian cancer patients. 10-year results of a prospective randomised phase III study comparing carboplatin-cisplatin with cyclophosphamide-cisplatin.
Dittrich Ch; Sevelda P; Salzer H; Obermair A; Speiser P; Breitenecker G; Schemper M; Kaider A;
Eur J Cancer; 2003 May; 39(8):1129-40. PubMed ID: 12736113
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
[TBL] [Abstract][Full Text] [Related]
25. A multicenter randomized Phase II trial of granulocyte-colony stimulating factor-supported, platinum-based chemotherapy with flexible midcycle cisplatin administration in patients with advanced ovarian carcinoma. PSAMOMA Cooperative Group, Spain.
Hidalgo M; Mendiola C; López-Vega JM; Castellano D; Mendez M; Batiste-Alenton E; López-Brea M; Belon J; Batista JN; Cortés-Funes H
Cancer; 1998 Aug; 83(4):719-25. PubMed ID: 9708936
[TBL] [Abstract][Full Text] [Related]
26. Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer.
Anderson H; Wagstaff J; Crowther D; Swindell R; Lind MJ; McGregor J; Timms MS; Brown D; Palmer P
Eur J Cancer Clin Oncol; 1988 Sep; 24(9):1471-9. PubMed ID: 3053207
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.
Conte PF; Bruzzone M; Carnino F; Chiara S; Donadio M; Facchini V; Fioretti P; Foglia G; Gadducci A; Gallo L
J Clin Oncol; 1991 Apr; 9(4):658-63. PubMed ID: 2066762
[TBL] [Abstract][Full Text] [Related]
28. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.
Neijt JP; Engelholm SA; Tuxen MK; Sorensen PG; Hansen M; Sessa C; de Swart CA; Hirsch FR; Lund B; van Houwelingen HC
J Clin Oncol; 2000 Sep; 18(17):3084-92. PubMed ID: 10963636
[TBL] [Abstract][Full Text] [Related]
29. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel.
Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A;
J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynäkologische Onkologie.
du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Bauknecht T; Warm M; Schroeder W; Olbricht S; Nitz U; Jackisch C
Semin Oncol; 1997 Aug; 24(4 Suppl 11):S11-28-S11-33. PubMed ID: 9314296
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Kohn EC; Sarosy GA; Davis P; Christian M; Link CE; Ognibene FP; Sindelar WF; Jacob J; Steinberg SM; Premkumar A; Reed E
Gynecol Oncol; 1996 Aug; 62(2):181-91. PubMed ID: 8751547
[TBL] [Abstract][Full Text] [Related]
32. High-dose platinum chemotherapy in advanced ovarian cancer: a phase II study.
Bertelsen K; Bastholt L
Gynecol Oncol; 1992 Jan; 44(1):79-82. PubMed ID: 1730430
[TBL] [Abstract][Full Text] [Related]
33. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
34. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
Fanning J; Hilgers RD
Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
[TBL] [Abstract][Full Text] [Related]
35. Combined cisplatin and carboplatin chemotherapy for treatment of advanced epithelial ovarian cancer.
Gershenson DM; Morris M; Burke TW; Levenback C; Kavanagh JJ; Fromm GL; Silva EG; Warner D; Wharton JT
Gynecol Oncol; 1995 Sep; 58(3):349-55. PubMed ID: 7672700
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer.
Teeling M; Hayes Y; Fitzmaurice B; McGing P; Carney DN
Semin Oncol; 1992 Feb; 19(1 Suppl 2):102-6. PubMed ID: 1411620
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
[TBL] [Abstract][Full Text] [Related]
39. Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.
Langer CJ; Leighton J; McAleer C; Comis R; O'Dwyer P; Ozols R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):64-9. PubMed ID: 7541156
[TBL] [Abstract][Full Text] [Related]
40. Continuous Low-Dose Oral Cyclophosphamide and Methotrexate as Maintenance Therapy in Patients With Advanced Ovarian Carcinoma After Complete Clinical Response to Platinum and Paclitaxel Chemotherapy.
El-Husseiny K; Motawei H; Ali MS
Int J Gynecol Cancer; 2016 Mar; 26(3):437-42. PubMed ID: 26825824
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]